Back to list

Insulin detemir in the management of type 2 diabetes in non-Western countries: Safety and effectiveness data from the A1chieve observational study

Alexey Zilov, Nabil El Naggar, Siddharth Shah, Chunduo Shen and Jihad Haddad

Diabetes Research and Clinical Practice, 3, 101, pages 317 - 325

Received 24 December 2012, Revised 16 May 2013, Accepted 6 June 2013, Published online Oct-2013

Article view:

6. Conclusion

People with T2D in poor glycaemic control who started treatment with insulin detemir in routine clinical care reported significant improvements in glycaemic control irrespective of prior treatment and geographical region after 24 weeks. These improvements were achieved without any safety or tolerability complications, and were associated with an improvement in patient self-assessment of HRQoL. These safety and effectiveness data for insulin detemir in the A1chieve study are consistent with those from previous study publications. The addition of evidence from predominantly less well-resourced countries expands the global picture of the role insulin detemir fulfils in real-life clinical practice.

Back to list